Meeting
2022 ASCO Genitourinary Cancers Symposium
Randomized phase II study of niraparib plus best supportive care (BSC) versus BSC alone as maintenance treatment in patients with advanced urothelial carcinoma (UC) whose disease did not progress after first-line platinum-based chemotherapy (PBCT): The Meet-URO12 trial.
Authors
Francesca Vignani
Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy
Francesca Vignani , Rosa Tambaro , Ugo De Giorgi , Patrizia Giannatempo , Davide Bimbatti , Claudia Carella , Marco Stellato , Francesco Atzori , Michele Aieta , Cristina Masini , Alketa Hamzaj , Paola Ermacora , Antonello Veccia , Sandro Pignata , Cristian Lolli , Giuseppe Procopio , Francesco Pierantoni , Antonia Zonno , Daniele Santini , Massimo Di Maio
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Urothelial Carcinoma
Track
Urothelial Carcinoma
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03945084
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 442)
DOI
10.1200/JCO.2022.40.6_suppl.442
Abstract #
442
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Full analysis from AVENANCE: A real-world study of avelumab first-line (1L) maintenance treatment in patients (pts) with advanced urothelial carcinoma (aUC).
First Author: Philippe Barthelemy
Poster
2024 ASCO Genitourinary Cancers Symposium
Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).
First Author: Inkeun Park
Poster
2023 ASCO Genitourinary Cancers Symposium
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.
First Author: Srikala S. Sridhar
Poster
2022 ASCO Annual Meeting
Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.
First Author: Begoña Pérez-Valderrama